United States-based Inovio Pharmaceuticals has received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to produce vaccine candidates against Lassa fever and Middle East Respiratory Syndrome, it was reported on Friday.
CEPI will fund up to USD56m to support the company's pre-clinical and clinical advancement through Phase two of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine.
The shared aim of Inovio and CEPI is for the Lassa and MERS vaccines to be offered for emergency use as soon as possible. This is the second company agreement that CEPI has signed since its launch in 2017. These collaborations are claimed to represent an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. The contract will allow funding for the company's development efforts over a five-year period. The collaboration agreement also includes options, not counted in the total above, to establish investigational stockpiles of both vaccines.
Micreos passes US FDA approval for PhageGuard-E to combat E. Coli O157
Valeo Pharma signs strategic agreement with Besins Healthcare
Roivant Sciences launches Respivant Sciences
US FDA grants rare paediatric disease designation to Cellectar Biosciences' CLR 131
Janssen submits erdafitinib's NDA with the US FDA for the treatment of metastatic urothelial cancer
Positive Cytisine Data Published in International Journal of Drug Policy
FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Disease